Navigation Links
INNOPHARMA Receives First FDA Approval
Date:2/2/2010

MONMOUTH JUNCTION, N.J., Feb. 2 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of the Abbreviated New Drug Application (ANDA) for ibutilide fumarate injection (the generic equivalent of Corvert® from Pfizer Inc).

As the developer of this generic injectable drug, INNOPHARMA entered into a license agreement with Bioniche Pharma USA for marketing and product distribution of the injection product. Ibutilide fumarate injection represents INNOPHARMA's first approved drug in their product pipeline.

Please refer to the Bioniche Pharma website to be directed to the complete prescribing information for this product, including the boxed warning.

About INNOPHARMA:

INNOPHARMA is a research and development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of parenteral pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.  

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anesthesiology, orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fue
'/>"/>

SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Mylan Receives Approval for Generic Version of GoLytely(R)
3. Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
4. Notal Visions ForeseeHome(TM) AMD Monitor Receives FDA Clearance
5. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
6. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
7. KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director
8. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
10. GeneGo Receives SBIR Grant
11. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... ANGELES , July 24, 2014  Bruin ... devices, announced today that after two weeks of ... throughout the European Union, it gained substantial concurrence ... moisture) and the clinical utility of BBI,s SEM ... over 90 percent of the respondents drawn from ...
(Date:7/24/2014)... Quebec , July 24, 2014 ... VRX ) (TSX:VRX) announced today that it has ... marches financiers ("AMF") regarding Allergan, Inc.,s (NYSE: ... and to negatively influence the market price of ... and misleading statements regarding Valeant,s business despite Valeant,s ...
(Date:7/24/2014)... , July 24, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... will release second quarter financial results after market close ... a webcast and conference call the same day at ... financial results and provide a corporate update. ...
Breaking Medicine Technology:Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 2
... Dec. 14, 2010 Biodel Inc. (Nasdaq: BIOD ... the company,s Chief Scientific Officer.  Dr. Steiner is a co-founder ... board of directors.  He served as Biodel,s chairman, president and ... March 2010 when Dr. Errol De Souza was named the ...
... announces that a new market research report is ... Pharmaceuticals Research Review http://www.reportlinker.com/p0341171/2010-Pharmaceuticals-Research-Review.html ... has accentuated the fault lines already dividing the ... pharma companies, coupled with the patent expiration precipice, ...
Cached Medicine Technology:Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 2Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 3Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 4Reportlinker Adds 2010 Pharmaceuticals Research Review 2Reportlinker Adds 2010 Pharmaceuticals Research Review 3Reportlinker Adds 2010 Pharmaceuticals Research Review 4Reportlinker Adds 2010 Pharmaceuticals Research Review 5Reportlinker Adds 2010 Pharmaceuticals Research Review 6Reportlinker Adds 2010 Pharmaceuticals Research Review 7Reportlinker Adds 2010 Pharmaceuticals Research Review 8Reportlinker Adds 2010 Pharmaceuticals Research Review 9Reportlinker Adds 2010 Pharmaceuticals Research Review 10Reportlinker Adds 2010 Pharmaceuticals Research Review 11Reportlinker Adds 2010 Pharmaceuticals Research Review 12Reportlinker Adds 2010 Pharmaceuticals Research Review 13Reportlinker Adds 2010 Pharmaceuticals Research Review 14
(Date:7/24/2014)... (PRWEB) July 24, 2014 Becker's Hospital ... "100 Hospitals and Health Systems With Great Oncology Programs." ... in terms of quality patient care, cancer outcomes and ... hospitals for inclusion based on rankings and awards they ... following awards were considered as part of the criteria ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The European Omega ... omega 3 & structured lipids market in Europe with analysis ... from around $670.37 million in 2012 to $989.91 million by ... , Browse through the TOC of the European omega 3 ... the in-depth analysis provided. This also provides a glimpse of ...
(Date:7/24/2014)... 24, 2014 The European air and missile ... 2014, and is expected to register a CAGR of 8.06%, ... Russia, and turkey are the major spenders in the region ... extended air defense program and multinational (MEADS) program, which has ... through the TOC of the Europe air and missile defense ...
(Date:7/24/2014)... p53 refers to cancer biology, and the functions of ... in detail. Furthermore, also in cancer biology, it is ... cells in order to block their metabolism and prevent ... research on p53 attempts to unveil its functions in ... cells. Recent studies with cell cultures have demonstrated that ...
(Date:7/24/2014)... malaria parasite becomes resistant to an investigational drug. ... in St. Louis, also is relevant for other ... The study appears July 24 in Nature ... that causes malaria, make a class of molecules ... organisms healthy, whether plants, animals or bacteria. In ...
Breaking Medicine News(10 mins):Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4Health News:Identified a key molecule in flies that adjusts energy use under starvation conditions 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3
... University of Alabama at Birmingham (UAB) this month became ... cancer radiation therapy. The new technique can turn a ... patients. , Additionally, the new therapy saves healthy human ... the same or better than other radiotherapy techniques, according ...
... MEDI3) (MEDIAL SAUDE) announces the following webcast:, What: Medial Saude ... 2008 @ 12:00 PM EDT, Where: http://prnewswire.isat.com.br/?palestra_id=305 , How: ... the address above., ... Toll-free from the US: (1 800) 860-2442; ...
... might be swaying clinicians , , WEDNESDAY, May ... overdiagnosed, say researchers at Rhode Island Hospital and ... half of patients previously diagnosed with bipolar disorder ... -- the Structured Clinical Interview for DSM-IV (SCID). ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... new data analysis that was conducted to examine ... boys and girls aged 6 to 12 years ... findings from the analysis reaffirmed that DAYTRANA has ...
... Agrees to $2.3 million fine, CARMEL, Ind., ... ),today announced a settlement among state insurance regulators ... Insurance (CSHI) Company,and Bankers Life and Casualty Company. ... by Pennsylvania, Illinois,Indiana, Texas and Florida related to ...
... Vail Valley ... Medical Center, VAIL, Colo., May ... today the appointment of the new President,and CEO, John H. Cassin. Cassin ... Medical Center., "John brings great leadership experience and an engaging personal,style, ...
Cached Medicine News:Health News:UAB first in US to offer speedier precise cancer radiotherapy 2Health News:Bipolar Disorder Might Be Overdiagnosed 2Health News:New analysis shows DAYTRANA offered ADHD symptom control for 12 months 2Health News:New analysis shows DAYTRANA offered ADHD symptom control for 12 months 3Health News:Conseco Reaches Settlement of Multistate Market Conduct Examination 2Health News:Vail Valley Medical Center Board of Directors Announces Appointment of New President & CEO, John Cassin 2
Karlin XL Magnum Ring Curettes, extra long (XL) curettes, black handles, lightweight. Length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
Hardy Curettes, bayonet, working distance 4 3/4" (120 mm), total length 9 1/2" (241 mm), tip width 3 mm....
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
Karlin Cervical Microdiscectomy Curette, length 8 1/2" (21 cm)....
Medicine Products: